Radiation Dose Study of Concurrent Chemoradiotherapy With Cisplatin Plus Fluorouracil in Oesophageal Cancer
연구 개요
상세 설명
Esophageal cancer (EC) continues to be a major health burden worldwide. The 5-year survival rates for esophageal cancer have remained less than 15% over decades, probably because of ineffective therapies and the detection of late-stage cancers. Concurrent chemo-radiotherapy was established as one of the viable options for therapy of patients with localized EC following the results from the landmark trial of the Radiation Therapy Oncology Group (RTOG) 85-01 trial, showing a significant survival advantage of concurrent chemoradiation over radiation alone.
The use of radiochemotherapy with cisplatin and 5-fluorouracil (5-FU) is a well-accepted standard for the definitive treatment of esophageal cancer in China which has also been demonstrated efficacy and good tolerability internationally. The AJCC recommended dose range of radiotherapy for concurrent therapy is 45-50.4Gy. Moreover, (RTOG) 85-01 trial also established 50.4 Gy as the standard dose of radiation to be administered concurrently with chemotherapy. However, the appropriate dose of radiation fit for Chinese remains controversial. Due to insufficient evidence of EBM, radiation therapist in China always prescribe a radiation dosage by their own experience. Dosages (e.g. 60-64Gy) significantly higher than the international standard is commonly used in Chinese EC patients which lead to a greater likelihood of toxicity. Thus Chinese oncologists are urgent to reach a consensus about radiation dosage in the standard treatment of local advanced EC.
연구 유형
등록 (예상)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
Jiangsu
-
Nanjing, Jiangsu, 중국, 210029
- Jiangsu Province Hospital
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Biopsy-proven squamous cell carcinoma or adenocarcinoma of thoracic or cervical esophagus or gastroesophageal junction esophagus, including the gastroesophageal junction
- Measurable lesion
- Age > 18 years
- Karnofsky performance score > 70
- Life expectancy > 3 months
- Adequate bone marrow function (white blood cell [WBC] count ≥ 3.5 109/L, neutrophil count ≥ 2.0 109/L, and platelet count ≥ 100 109/L), adequate renal function (creatinine ≤ 2 mg/dL or creatinine clearance ≥ 50 mL/min), and normal liver function (aspartate aminotransferase and alanine aminotransferase less than two times the upper limit of normal, total serum bilirubin ≤ 1.5 mg/dL).
Exclusion Criteria:
- Prior systemic chemotherapy for EC
- Evidence of distant metastatic disease
- Evidence of uncontrolled medical conditions (e.g.,serious infection,grade 4 hypertension,congestive heart failure)
- A history of concomitant or previous malignancy.
- Physical evidence of peripheral neuropathy or hearing loss
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Concurrent radiochemotherapy
|
initial dose:50Gy/2Gy/25f,5days/week escalation dose:4Gy/2Gy/2f
cisplatin 75 mg/m2 on day 1 with standard hydration fluorouracil 1000 mg/m2/day1 i.v. by continuous infusion from day 1 to day 4 of each cycle
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Objective Tumor Response
기간: One day after completion of the initial therapeutic dose (50.0Gy) and the total dose of radiotherapy
|
objective evaluation is made according to the standards of Response Evaluation Criteria in Solid Tumors (RECIST)，defined as complete response(CR),partial response (PR)，stable disease(SD),and progressive disease (PD).Tumor sizes are measured using barium esophagram or CT.
|
One day after completion of the initial therapeutic dose (50.0Gy) and the total dose of radiotherapy
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
adverse events
기간: Side effect assessment was performed every week for the duration of concurrent radiochemotherapy, an expected average of 5 weeks
|
using the National Cancer Institute Common Toxicity Criteria,predominantly observe the presence of radiation esophagitis,radiaion pneumonia and hematological toxicity.
|
Side effect assessment was performed every week for the duration of concurrent radiochemotherapy, an expected average of 5 weeks
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Xinchen Sun, M.D.,Ph.D., The First Affiliated Hospital with Nanjing Medical University
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (예상)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
식도 신생물에 대한 임상 시험
-
University of Sao PauloW.L.Gore & Associates; InCor Heart Institute종료됨
Megavoltage photon beam에 대한 임상 시험
-
Beam Therapeutics Inc.모병
-
National Institutes of Health Clinical Center (CC)완전한
-
Beam Therapeutics Inc.모병건강한 과목 | 건강한 참가자 연구영국
-
University of CalgaryAlberta Children's Hospital; Provincial Health Services Authority; Brain Canada; MindSea Development 그리고 다른 협력자들모병
-
University of ManitobaUniversity of Calgary; Tactica Interactive; Centre for Healthcare Innovation; Research Manitoba알려지지 않은
-
Beam Therapeutics Inc.모병알파 1-항트립신 결핍증뉴질랜드, 영국, 호주, 네덜란드, 미국, 아일랜드